Chelsea Therapeutics International News

Shares of Chelsea Therapeutics International traded down 33.33% during mid-day trading on Thursday, hitting $1.30. Chelsea Therapeutics International has a 52 week low of $1.91 and a 52 week high of $6.06. The company's market cap is $87.2 million.

Chelsea Therapeutics International Ltd said it will stop developing its experimental drug for rheumatoid arthritis after the treatment failed a mid-stage study, sending its shares down 27 percent before the bell.

Chelsea Therapeutics International Lead Plaintiff Deadline - June 4, 2012: Levi & Korsinsky Reminds Investors with Losses on Their Investment in Chelsea Therapeutics International of Class Action and the Lead Plaintiff Deadline Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the ... (more)

The Rosen Law Firm, P.A. reminds investors of the important June 4, 2012 lead plaintiff deadline in the securities class action on behalf of purchasers of Chelsea Therapeutics International, Ltd.

NEW YORK, May 26, 2012 -- The Rosen Law Firm, P.A. reminds investors of the important June 4, 2012 lead plaintiff deadline in the securities class action on behalf of purchasers of Chelsea Therapeutics International, Ltd.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Chelsea Therapeutics, Inc.

Chelsea Therapeutics International Ltd. said Tuesday it may have to make changes to a clinical trial of its drug candidate Northera, potentially delaying its approval.

Shareholders of Chelsea Therapeutics International Ltd. are reminded of the securities class action filed against Chelsea and certain of its officers.